A UK-headquartered company is supplying lethal injection drugs to Arkansas Death Row, it has emerged.
The US state recently announced that it was moving to a new execution drug, called phenobarbital, after supplies of previously-used drugs were shut off by companies which did not want to see their products used to execute.
It has since been revealed that Arkansas Department of Corrections (DoC) obtained the phenobarbital from West-Ward pharmaceuticals, a wholly-owned subsidiary of Hikma plc, which has its headquarters in London.
Recent moves by a number of global pharmaceutical companies – including Lundbeck, Fresenius Kabi, Teva and Hospira – to restrict the supply of a number of barbiturates in order to prevent their use in executions has left prisons in the US struggling to find the means by which to carry out the death penalty.
However, despite being warned by human rights charity Reprieve that their drugs are being used in this way, neither parent company Hikma nor West-Ward have yet followed the example of their competitors in taking concrete steps to restrict supply.
Arkansas is the first – and so far, the only – state to switch to phenobarbital, which has not previously been used in executions. Papers filed with courts in the US have pointed out that the untested nature of the drug in this context may result in prisoners not necessarily being killed but instead left in a “vegetative state” or with “devastating injuries that will cause prolonged suffering.”
Maya Foa, Deputy Head of Reprieve’s Death Penalty Team said: “It’s very disappointing to see a British firm fuelling executions in the USA. Hikma claims to be ‘committed to improving people’s lives’ yet the firm is apparently happy for its drugs to be used in the potentially torturous executions of prisoners in the USA. This callous indifference to the suffering of prisoners and disregard for corporate social responsibility is all the more surprising in light of the ethical steps taken by other manufacturers implicated in the execution drug trade. Hikma knows that it can prevent its drugs from being used to kill, just as other firms have done, yet it is choosing to do nothing. If no action is taken, Hikma may soon become the prime provider of execution drugs across the USA.”
Source: Reprieve, May 15, 2013